-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

ii This approval underscores GSK's commitment to help drive progress for people living with complex blood cancers.

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Constellation Energy is preparing to restart what's now called the Crane Clean Energy Center on Three Mile Island to supply ...

DelveInsight's Glucose Syrup Market Insights report provides the current and forecast market analysis, individual leading ...

Requesting deletion closes your account permanently and prevents your data from being used in further research (existing ...

Legalcategory GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln October 9, 2024 Healthcare & Pharmaceuticalscategory GSK, Pfizer RSV vaccine sales fall in US as millions fewer ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...